The Global. Biosimilar drugs were presented on the market as an option to democratize access. This is how the majority of European administrations have seen it, although some have reached very high levels that could endanger those therapies that they use to generate savings. On June 30, during a meeting of Infarmed —the Portuguese Aemps— various examples of price reductions for biological drugs were given to increase their share of market penetration. One of them was the filgrastim case, whose share in the Portuguese country, according to its decision-makers, has reached 100 percent after a 77 percent depreciation compared to the reference biological drug. "From having a bill of 7,5 million euros we have gone to less than 2 million euros," he defended himself during the day.

READ MORE